Nipro Medical

Nipro Corporation is a Japanese company engaged in the medical devices, pharmaceuticals, and pharmaceutical packaging sectors. Founded in 1954 and headquartered in Osaka, Nipro develops and manufactures a wide range of disposable medical products, focusing primarily on renal care, intervention and anesthesiology, injection and infusion, dialysis, cardiopulmonary, and diabetic products. The company also produces artificial organ-related items and generic drugs. Its pharmaceutical segment offers combination products such as pre-filled syringes and transdermal systems, alongside contract manufacturing services. Additionally, Nipro's pharmaceutical packaging division provides glass vials, syringes, and other packaging components essential for the industry. Nipro serves a diverse customer base across Japan, the Americas, China, Europe, and other regions of Asia. The company is recognized for its significant contributions to the medical field, particularly in renal products, which represent the largest share of its revenue.

6 past transactions

InVera Medical

Seed Round in 2020
Venari Medical’s mission focus is on the innovation of unparalleled safe, effective, patient-centered medical devices that improve quality of life for those with debilitating vascular disease. Venari Medical are developing BioVena™ - a more effective, less invasive, and faster treatment for all venous disease patients. It is uniquely positioned to disrupt current treatment practices which have seen only medium level innovation in the past decade. The team is based at Ireland's medtech cluster in Galway. Only 1.3 million of the 120 million people in the US & EU who suffer from venous disease currently receive endovenous treatment each year. 3 million venous ulcer patients are completely unserved, using ineffective compression bandaging. Venari Medical offers an unrivaled lower risk and unparalleled effective non-thermal treatment which will allow more patients who suffer from Venous Disease to access effective treatment. The indication for the use of superficial venous ablation is also set to widen to treat venous ulcers that currently incur annual costs of $33Bn to insurers in the US & EU. The Venari Medical technology can be used as a safe and effective treatment for the whole spectrum of Venous Disease from varicose veins to active venous ulcers.

TC BioPharm

Series A in 2017
TC BioPharm develops safer, cheaper, consistent, and durable CAR-T drugs for hematological and solid tumors. TC BioPharm’s mission is to develop and commercialize innovative cell-based products to treat disease, improving patient health and quality of life. TC BioPharm is a clinical development company with a cell-based product pipeline capable of treating a variety of disorders, including cancer and severe viral infections. TCB is currently conducting Phase II/III clinical studies of its lead product, ImmuniCell, in renal cell cancinoma, non-small cell lung cancer and melanoma patients.

InfraReDx

Acquisition in 2015
InfraReDx, Inc. designs, develops, manufactures, and distributes medical devices. The company specializes in near-infrared spectroscopic (NIRS) technology and its application to coronary imaging. It develops a fiber-optic, catheter-based, near-infrared (NIR) spectroscopy system to identify and characterize vulnerable plaque in the coronary arteries. The company was founded in 1998 and is headquartered in Burlington, Massachusetts.

Cell Science Laboratory

Acquisition in 2014
Cell Science Laboratory provides development and manufacture and sale of research and culture solution for cell culture.

InfraReDx

Private Equity Round in 2013
InfraReDx, Inc. designs, develops, manufactures, and distributes medical devices. The company specializes in near-infrared spectroscopic (NIRS) technology and its application to coronary imaging. It develops a fiber-optic, catheter-based, near-infrared (NIR) spectroscopy system to identify and characterize vulnerable plaque in the coronary arteries. The company was founded in 1998 and is headquartered in Burlington, Massachusetts.

Home Diagnostics

Acquisition in 2010
Home Diagnostics is a developer, manufacturer and marketer of blood glucose monitoring systems and disposable supplies for diabetics. Our blood glucose monitoring systems offer diabetics performance and features that are comparable to or better than our competitors products, in most cases at a substantially lower price.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.